Prognostic Value of the MAGNIMS Score and its Application in Clinical Outcome Assessment of Disease Modifying Therapy in Patients with Relapsing Multiple Sclerosis: Results from the OPTIMUM Study of Ponesimod

被引：0
|
作者：
Keenan, A. [1 ]
Gandhi, K. [1 ]
Le, H. H. [1 ]
Turkoz, I. [1 ]
Guo, S. [2 ]
Liao, W.
Pelligra, C. G. [3 ]
机构：
[1] Janssen Pharmaceut, Titusville, NJ USA
[2] Evidera, Waltham, MA USA
[3] Evidera, Bogota, Colombia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P085
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [11] Real-world demographics, clinical characteristics and treatment patterns in relapsing multiple sclerosis patients on disease-modifying therapy
    Ziemssen, T.
    Kurzeja, A.
    Haas, J.
    Alexander, J.
    Driessen, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 547 - 548
  • [12] Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries
    Visintin, Erica
    Tinelli, Michela
    Kanavos, Panos
    HEALTH POLICY, 2019, 123 (02) : 118 - 129
  • [13] Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study
    Fox, Robert
    Kappos, Ludwig
    Burcklen, Michel
    Freedman, Mark
    Havrdova, Eva
    Hennessy, Brian
    Hohlfeld, Reinhard
    Lublin, Fred
    Montalban, Xavier
    Pozzilli, Carlo
    Scherz, Tatiana
    Linscheid, Philippe
    Pirozek-Lawniczek, Magdalena
    Kracker, Hilke
    Sprenger, Till
    NEUROLOGY, 2020, 94 (15)
  • [14] The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study
    Pappalardo, Angelo
    Chisari, Clara Grazia
    Montanaric, Enrico
    Pesci, Ilaria
    Borriello, Giovanna
    Pozzilli, Carlo
    D'Amico, Emanuele
    Patti, Francesco
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 17 : 154 - 171
  • [15] Favorable response to disease modifying treatments in Chinese patients with relapsing multiple sclerosis - results from a prospective registry in Hong Kong
    Au, C. K.
    Ng, A.
    Mok, V.
    Lau, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 951 - 951
  • [16] A retrospective assessment of the clinical profile in patients with relapsing-remitting multiple sclerosis treated with disease modifying treatment - "PROFIL-SM"
    Donath, V.
    Lisy, L.
    Prochazkova, L.
    Szilasiova, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 227 - 227
  • [17] A two-year, observational study of patients with relapsing-remitting multiple sclerosis to assess the outcome of switching between disease-modifying therapy class in routine UK clinical practice
    Rog, D.
    O'Riordan, J.
    Mottershead, J. P.
    Croft, D.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 448 - 448
  • [18] Prognostic indicators of future disease activity in patients with relapsing multiple sclerosis (MS): an analysis from the AFFIRM study
    Kappos, L
    O'Connor, PW
    Havrdova, E
    Hutchinson, M
    Miller, DH
    Phillips, JT
    Polman, CH
    Lublin, FD
    Giovannoni, G
    Wajgt, A
    Lynn, F
    Toal, M
    Panzara, MA
    Sandrock, AW
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S75 - S75
  • [19] An alternative approach to estimate the health economic value of a non-disease modifying therapy for patients with multiple sclerosis: a Swedish application
    Leskela, R. -L.
    Dahlman, M.
    Gaebler, J. A.
    Deniz, B.
    Sarda, S.
    Herse, F.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 479 - 479
  • [20] Patients reported outcome measures from relapsing remitting people with multiple sclerosis on first line disease modifying therapies in a real world settin
    Bonavita, S.
    Lavorgna, L.
    Signori, A.
    Signoriello, E.
    Cepparulo, S.
    Carmisciano, L.
    Maniscalco, G. T.
    Strianese, A.
    Sacca, F.
    Lus, G.
    Morra, V. Brescia
    Sparaco, M.
    Lanzillo, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 826 - 826
12345